Brickell's sofpironium bromide meets in Phase IIb for hyperhidrosis

In October, Brickell Biotech Inc. (Boulder, Colo.) reported data from a double-blind, U.S. Phase IIb trial in 227 patients with primary axillary hyperhidrosis showing that 5%,

Read the full 261 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE